公开(公告)号：US10513534B2

公开(公告)日：2019-12-24

申请号：US14047862

申请日：2013-10-07

Applicant: IDENIX PHARMACEUTICALS LLC ,  Centre National De La Recherche Scientifique ,  UNIVERSITE DE MONTPELLIER

Inventor： Gilles Gosselin ,  Christophe Claude Parsy ,  Francois-Rene Alexandre ,  Houcine Rahali ,  Jean-Francois Griffon ,  Dominique Surleraux ,  Cyril B. Dousson ,  Claire Pierra ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Alistair James Stewart

IPC: C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  C07H19/11 ,  C07H19/16 ,  C07H19/173 ,  C07H19/20 ,  C07H19/213 ,  A61K31/7072 ,  A61K45/06 ,  A61K38/21 ,  A61K31/7076 ,  C07H19/14 ,  A61K31/7064 ,  C07H19/12 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/708 ,  A61K31/403 ,  A61K31/497 ,  A61K31/7105 ,  C07H19/23

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

公开(公告)号：US10238680B2

公开(公告)日：2019-03-26

申请号：US14954815

申请日：2015-11-30

Applicant: IDENIX PHARMACEUTICALS LLC ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER

Inventor： Benjamin Alexander Mayes ,  Adel M. Moussa ,  Cyril B. Dousson ,  Gilles Gosselin ,  Claire Pierra ,  David Dukhan

IPC: C07H19/10 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  A61K9/00

Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.

公开(公告)号：US10231986B2

公开(公告)日：2019-03-19

申请号：US14866759

申请日：2015-09-25

Applicant: Centre National De La Recherche Scientifique ,  Universite Montpellier 2 Sciences Et Techniques ,  Idenix Pharmaceuticals LLC

Inventor： David Dukhan ,  Christophe Claude Parsy ,  Gilles Gosselin ,  Jean-François Griffon ,  Guillaume Brandt ,  Cyril B. Dousson ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Alistar James Stewart

IPC: C07H19/073 ,  C07H19/10 ,  C07H19/173 ,  C07H19/20 ,  A61K31/7072 ,  C07H17/02 ,  A61K31/7068 ,  A61K45/06 ,  A61K9/00 ,  A61K31/7076

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.

公开(公告)号：US10202411B2

公开(公告)日：2019-02-12

申请号：US15304506

申请日：2015-04-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： David Dukhan ,  Cyril B. Dousson ,  Gilles Gosselin ,  Jean-Laurent Paparin ,  Guillaume Brandt ,  Rachid Rahali ,  Aurelien Salanson ,  François-René Alexandre

IPC: A01N43/04 ,  A61K31/70 ,  C07H19/20 ,  C07H19/10 ,  C07H19/11 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/7064 ,  A61K31/708 ,  A61K31/7052 ,  A61K31/706

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

公开(公告)号：US10005779B2

公开(公告)日：2018-06-26

申请号：US14296122

申请日：2014-06-04

Applicant: Idenix Pharmaceuticals LLC

Inventor： David Dukhan ,  Gilles Gosselin ,  Cyril B. Dousson

IPC: C07D409/04 ,  C07D473/18 ,  A61K31/506 ,  A61K31/522 ,  A61K45/06 ,  C07H19/067

CPC classification number: C07D473/18 ,  A61K31/506 ,  A61K31/522 ,  A61K45/06 ,  C07D409/04 ,  C07H19/067

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 1′,4′-thio nucleoside compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof; wherein Base, RA, RB, W, X, Y, and Z are as described herein.

公开(公告)号：US20210024565A1

公开(公告)日：2021-01-28

申请号：US17061409

申请日：2020-10-01

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari ,  Centre National De La Recherche Scientifique ,  Universite de Montpellier

Inventor： Richard Storer ,  Gilles Gosselin ,  Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: C07H19/16 ,  A61K47/60 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  A61K38/21 ,  A61K45/06 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/22 ,  A61K31/7068 ,  A61K31/708 ,  C07H19/056 ,  C07H19/06 ,  A61K31/7056 ,  A61K9/20 ,  A61K9/48

Abstract: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

公开(公告)号：US20180237467A1

公开(公告)日：2018-08-23

申请号：US15890990

申请日：2018-02-07

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari ,  Centre National De La Recherche Scientifique ,  Universite de Montpellier

Inventor： Richard Storer ,  Gilles Gosselin ,  Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: C07H19/16 ,  A61K31/7056 ,  A61K45/06 ,  C07H19/06 ,  C07H19/056 ,  A61K38/21 ,  A61K31/708 ,  A61K31/7068 ,  A61K47/60 ,  A61K9/48 ,  A61K9/20 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  C07H19/22 ,  C07H19/048 ,  C07H19/04 ,  C07H19/00

CPC classification number: C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

Abstract: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.